Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a US-based immunology company, announced on Monday that it has named Anne Altmeyer, PhD, MBA, MPH as its new director.
Presently, Dr Altmeyer is the president and CEO of TigaTx, Inc. She has earlier served as the chief business officer for Sigilon Therapeutics and Adicet Bio. She has also served in roles of increasing responsibility in corporate development and program management for more than 15 years across large pharmaceutical organisations. Dr Altmeyer has previously held the position of vice president in Global Business Development at Baxalta and vice president in Oncology Business Development and Companion Diagnostics at Novartis. She started her industry career in program management roles at Merck & Company.
Dr Altmeyer holds PhD from the University Louis Pasteur, Strasbourg, France, postdoctoral fellowships at New York University and Cornell University Medical College in New York City, MBA from Rutgers University and a Masters in Public Health from the Robert Wood Johnson Medical School, in New Jersey.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates